A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

Title
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis
Authors
Keywords
Volixibat, SHP626, LUM002, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease, Apical sodium-dependent bile acid transporter (ASBT), Cholesterol, Obesity
Journal
BMC Pharmacology & Toxicology
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-04
DOI
10.1186/s40360-018-0200-y

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search